Source: CureToday articles
Alternating between Glivec and Stivarga therapy didn’t impact survival outcomes; it led to more toxicity and discontinuations in patients with GIST.
Recent Content
- Asembia AXS25: Advancing nAMD and DME Treatments: Pharmacists’ Role in Patient Care and Therapy Optimization
- Asembia AXS25: Navigating the Evolving Landscape of GLP-1 Medications
- Revised free light chain reference intervals enhance risk stratification in monoclonal gammopathy of undetermined significance and reduce overdiagnosis
- Investigational LUT014 Gel Improves Acneiform Rash in Patients With Metastatic Colorectal Cancer
- Alternating Glivec and Stivarga Doesn’t Improve Advanced GIST Outcomes
- A Dose of Inspiration: Celebrating the Pharmacist-Patient Relationship During Patient Experience Week
- Breast MRI Offers Sensitive Imaging for High-Risk and Diagnosed Patients
- Neoadjuvant Mitomycin C Shows Favorable Safety in Bladder Cancer
- AACR 2025: High Response Rates With Dostarlimab Suggest New Standard for dMMR Treatment
- How Mammogram Reminders Can Be More Thoughtful Following Breast Cancer